Welcome to our dedicated page for Alpine Immune Sciences news (Ticker: ALPN), a resource for investors and traders seeking the latest updates and insights on Alpine Immune Sciences stock.
Founded in 2015, Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is a leading clinical-stage biotechnology company dedicated to developing innovative protein-based immunotherapies to treat autoimmune and inflammatory diseases. Alpine leverages its unique understanding of immunology, particularly recombinant protein-based immunotherapies, to modify the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases.
Alpine's standout product, povetacicept (ALPN-303), is a dual antagonist of the BAFF and APRIL cytokines. This product is currently in phase 2 development and has demonstrated potential best-in-class efficacy for treating IgA nephropathy (IgAN). IgAN is a serious, progressive kidney disease with no approved therapies that target its underlying cause. Povetacicept has exhibited promising results in reducing proteinuria, stabilizing renal function, and reducing key disease-related biomarkers.
Additionally, Alpine has a robust pipeline, including acazicolcept (ALPN-101), a first-in-class dual inhibitor targeting the CD28 and ICOS T-cell costimulatory pathways. This drug is being investigated for treating systemic lupus erythematosus (SLE) and other autoimmune diseases. Alpine's research and development capabilities are enhanced by strategic collaborations with leading global biopharmaceutical companies, propelling its efforts to create multifunctional immunotherapies that improve patients' lives.
The company has been highly productive in the past year, achieving significant milestones, such as the phase 2 study of acazicolcept in SLE, a pivotal phase 3 trial of povetacicept in IgAN planned for the second half of 2024, and successful financial activities supporting ongoing and future development projects.
Alpine Immune Sciences remains committed to innovation, with ongoing studies in various autoimmune diseases and strategic goals aligning with its mission to lead a new wave of immune therapeutics.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) reported its Q1 2022 financial results and corporate updates, revealing significant progress in its clinical pipeline. The company highlighted promising data for davoceticept, showing a 23% tumor volume reduction in evaluable participants during trials. They have also opened monotherapy expansion cohorts for patient enrollment. Financially, ALPN posted $219.1 million in cash and cash equivalents, and collaboration revenue surged to $13.6 million, up from $3.2 million a year prior. However, they recorded a net loss of $7.5 million.
Alpine Immune Sciences, Inc. (Nasdaq: ALPN) will participate in two investor conferences in May 2022. The LifeSci Partners Immunology & Inflammation Symposium is scheduled for May 10 at 3:00 p.m. ET, featuring a fireside chat. The BofA Securities Healthcare Conference 2022 will occur on May 11 at 7:15 p.m. ET, where the company will present corporately. Webcasts of both events will be accessible on their investor relations website for 90 days after the live presentations. Alpine is focused on developing innovative immunotherapies for cancer and autoimmune diseases.
Alpine Immune Sciences (NASDAQ: ALPN) reported promising results from its ongoing NEON-1 study of davoceticept, a novel immunotherapy for advanced malignancies. In a heavily pretreated cohort, 23% of participants showed tumor volume reduction. Notably, 54% achieved clinical benefit, with two partial responses observed. The treatment exhibited favorable tolerability with minimal adverse effects. Future expansion cohorts are planned for tumor types such as melanoma and renal cell carcinoma, marking a significant step in Alpine's clinical development pipeline.
Alpine Immune Sciences will host a virtual investor event on
Alpine Immune Sciences (Nasdaq: ALPN) announced a publication in Nature Communications detailing the preclinical development of davoceticept, its lead immuno-oncology candidate targeting CD28 and PD-L1. The study highlights davoceticept's unique mechanism, which combines CD28 costimulation with dual checkpoint inhibition. Clinical trials, NEON-1 and NEON-2, are ongoing, with NEON-1 data to be presented at the AACR Annual Meeting on April 12. The promising results encourage continued development amidst a partial clinical hold on NEON-2.
Alpine Immune Sciences (Nasdaq: ALPN) will host a virtual investor event on April 12, 2022, at 6:00pm ET, coinciding with the AACR Annual Meeting. The event will provide a corporate update and discuss the development strategy for davoceticept (ALPN-202), including insights from its oral presentation at the meeting. Participants can join via phone or webcast, with a replay available for 90 days. Davoceticept is a first-in-class immunotherapy for cancer treatment, showing superior efficacy in preclinical studies.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced significant growth in 2021, with $176 million raised through partnerships and financing. The company is advancing three clinical-stage programs, with davoceticept phase 1 data to be presented at the 2022 AACR Annual Meeting. ALPN-303 is also progressing, with data expected in mid-2022. Financial results showed a net loss of $50.3 million for 2021, compared to $27.9 million in 2020, with a notable increase in collaboration revenue from $9.3 million in 2020 to $23.4 million in 2021. Cash and investments totaled $215.4 million as of December 31, 2021.
Alpine Immune Sciences (NASDAQ: ALPN) has announced that an abstract for the NEON-1 clinical trial results of davoceticept (ALPN-202) will be presented at the AACR Annual Meeting in New Orleans from April 8-13, 2022. This Phase 1 clinical trial focuses on the monotherapy dose escalation of davoceticept in patients with advanced malignancies. The presentation is scheduled for April 12 from 2:30 pm to 4:30 pm CDT, showcasing promising outcomes as Alpine progresses in its immunotherapy development.
Alpine Immune Sciences announced a partial clinical hold on its NEON-2 trial evaluating davoceticept (ALPN-202) in combination with pembrolizumab after a Grade 5 serious adverse event, resulting in patient death. The incident was linked to potential immune-mediated myocarditis. Despite this setback, the ongoing NEON-1 trial of davoceticept as a monotherapy remains unaffected. The company emphasizes patient safety and expects to work with the FDA and partners to resume the NEON-2 trial with safety precautions after review.
Alpine Immune Sciences, Inc. (NASDAQ: ALPN) announced participation in two major investor conferences in March 2022. The company will engage in fireside chats at Cowen's 42nd Annual Health Care Conference on March 7 at 2:50 p.m. ET, and Oppenheimer's 32nd Annual Healthcare Conference on March 17 at 2:40 p.m. ET. Webcasts will be accessible on their investor relations website, with replays available for 90 days. The company focuses on pioneering immunotherapy treatments for cancer and autoimmune disorders through advanced protein engineering technologies.
FAQ
What is the current stock price of Alpine Immune Sciences (ALPN)?
What is the market cap of Alpine Immune Sciences (ALPN)?
What does Alpine Immune Sciences, Inc. specialize in?
What is povetacicept (ALPN-303)?
What are the core focus areas of Alpine Immune Sciences?
What recent achievement has Alpine Immune Sciences accomplished?
What is acazicolcept (ALPN-101)?
What collaborations has Alpine Immune Sciences engaged in?
What is the ticker symbol for Alpine Immune Sciences?
When was Alpine Immune Sciences founded?
What is the mission of Alpine Immune Sciences?
Where can more information about Alpine Immune Sciences be found?
